Abstract

The Marrow Transplantation Program Project is an integrated, interdisciplinary program in transplantation. Pre-clinical and clinical studies interdigitate oncology, immunology, and hematology with molecular biology, pharmacology and experimental marrow transplantation. Studies of chronic myelocytic leukemia (CML) are directed at cytokines and adherent-LAK cells for reduction of residual disease in autologous and allogeneic transplantation. Recombinant viruses containing IL-1 and IL-2 cytokines with anti-tumor effects are to be developed. Studies of autologous marrow transplantation in non-Hodgkin's lymphomas will compare marrow and peripheral blood stem cells. Pre-clinical studies of lymphoblastic leukemia concentrate on immunotoxins and leukemic progenitor cells. Clinical studies of high risk acute lymphoblastic leukemia focus on marrow transplantation comparing autologous, sibling and unrelated allogeneic transplantation. New immunotherapeutic approaches for refractory high risk ALL including cytokines, antibodies and immunotoxins are to be studied. B-cell dysfunction following bone marrow transplantation will be studied. Cyclosphamide pharmacodynamics is under study. Studies of the pathogenesis, diagnosis and treatment of cytomegalovirus are emphasized. Marrow transplantation across minor histocompatibility barriers is under study in mouse models.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA021737-18
Application #
2086971
Study Section
Special Emphasis Panel (SRC (H1))
Project Start
1984-03-01
Project End
1996-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
18
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455

  Publications

Flynn, Catherine M; Hirsch, Betsy; Defor, Todd et al. (2007) Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 82:867-72
Orchard, Paul J; Blazar, Bruce R; Wagner, John et al. (2007) Hematopoietic cell therapy for metabolic disease. J Pediatr 151:340-6
Grewal, Satkiran S; Barker, Juliet N; Davies, Stella M et al. (2003) Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 101:4233-44
Wagner, John E; Barker, Juliet N; DeFor, Todd E et al. (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100:1611-8
Sladek, Norman E (2002) Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat Res 112:161-75
Browne, P V; Weisdorf, D J; DeFor, T et al. (2000) Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26:865-9
Delforge, M; Boogaerts, M A; McGlave, P B et al. (1999) BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal. Blood 93:284-92
Warwick, A B; Mertens, A C; Shu, X O et al. (1998) Outcomes following mechanical ventilation in children undergoing bone marrow transplantation. Bone Marrow Transplant 22:787-94
Katsanis, E; Weisdorf, D J; Miller, J S (1998) Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Bone Marrow Transplant 22:185-91
Arns da Cunha, C; Weisdorf, D; Shu, X O et al. (1998) Early gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant 21:173-80

Showing the most recent 10 out of 416 publications